The following criteria is provided for health care professionals.

Inclusion Criteria:

1. Men or women ≥ 18 years old at the time of signing the ICF
2. Men or women ≥ 18 years old at the time of signing the ICF,
   • Patient with a CRC, epithelial ovarian cell or fallopian tube carcinoma, urothelial carcinoma, TNBC, pancreatic cancer, AML/MDS or MM,
   • Disease must be measurable according to the corresponding guidelines,
   • Patient with an ECOG performance status 0 or 1, and AML patients with anemia resulting in an ECOG performance status of 2,
   • Patient with adequate bone marrow reserve, hepatic and renal functions.
   • Patients must have sufficient pulmonary functions with a Forced Expiratory Volume in the first second (FEV-1)/Forced Vital Capacity (FVC) ≥ 0.7 with FEV-1 ≥ 50% predicted.

Detailed disease specific criteria exist and can be discussed with site contacts.

Exclusion Criteria:

Main inclusion criteria are:

• Men or women ≥ 18 years old at the time of signing the ICF,
• Patient with a CRC, epithelial ovarian cell or fallopian tube carcinoma, urothelial carcinoma, TNBC, pancreatic cancer, AML/MDS or MM,
• Disease must be measurable according to the corresponding guidelines,
• Patient with an ECOG performance status 0 or 1, and AML patients with anemia resulting in an ECOG performance status of 2,
• Patient with adequate bone marrow reserve, hepatic and renal functions.
• Patients must have sufficient pulmonary functions with a Forced Expiratory Volume in the first second (FEV-1)/Forced Vital Capacity (FVC) ≥ 0.7 with FEV-1 ≥ 50% predicted.

Main exclusion criteria are:

• Patient with a tumor metastasis in the central nervous system,
• Patients who have received another cancer therapy within 2 weeks before the planned day for the apheresis (except hydroxyurea for AML patients),
• Patients who receive or are planned to receive any other investigational product within the 3 weeks before the planned day for the first NKR-2 administration (except hydroxyurea for AML patients),
• Patient is under systemic immunosuppressive drugs, unless specific cases authorized per protocol,
• Patients who have received other cell therapies,
• Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration.
• Patient cannot present with history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis and/or active or acute exacerbation of chronic obstructive pulmonary disease (COPD).